Depixus, a leading innovator in the field of intereactomics, has been awarded the prestigious Ignite Award at the Society for Laboratory Automation and Screening (SLAS) annual International Conference and Exhibition in Boston, MA. This recognition comes after the company’s groundbreaking MAGNA™ technology was featured in the conference’s dedicated area for start-ups and emerging companies.
The Ignite Award is given to companies that are pushing the boundaries of innovation in life sciences with their advanced technologies. To be considered for this award, participants were evaluated based on several criteria including excellence in innovation, marketing presence, impact, funding, and balanced leadership. Out of 16 participating companies, Depixus was one of only eight finalists selected for this prestigious award.
MAGNA One is a revolutionary technology that uses magnetic force spectroscopy to analyze dynamic biomolecular interactions at high speeds. This cutting-edge tool can measure real-time interactions from thousands of individual molecules simultaneously, making it an ideal choice for studying challenging targets such as RNA and protein-protein interactions. By providing valuable insights into disease mechanisms and accelerating the development of novel therapeutics, MAGNA One has enormous potential to impact patient care.
Depixus CEO Gordon Hamilton expressed his excitement about receiving the Ignite Award, highlighting the importance of innovative technology in advancing our understanding and treatment of diseases where new treatments are urgently needed. Chief Commercial Officer Steve Klose added that winning this award coincides perfectly with their technology access program launch and commercial rollout of MAGNA One – a significant milestone for the company’s growth and success.
For more information about Depixus or its MAGNA One technology, visit depixus.com or contact Steve Klose at firstname.lastname@example.org